


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.072A2	APPLICATION NO. 09/940,101
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT GERRITSEN et al.	
		FILING DATE August 27, 2001	GROUP 1641



SHEET 1 OF 3

RECEIVED  
JAN 07 2002  
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
MB	1	4,968,603	11/06/90	Slamon et al.	435	6	12/31/86
	2	5,183,884	02/02/93	Kraus et al.	536	23.5	12/01/89
	3	5,641,869	06/24/97	Vandler et al.	530	413	05/31/95
MB	4	5,821,337	10/13/98	Carter et al.	530	387.3	08/21/92

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
MB	5	WO 99/19488	22.04.99	PCT				
↓	6	0 444 961 A1	04.09.91	EPO				
MB	7	0 599 274 A1	01.06.94	EPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
MB	8	Andres, V., "Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis (Review)," <u>International Journal of Molecular Medicine</u> , Vol. 2, pp. 81-89 (1998).	
	9	Baselga, J. et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 <sup>HER2</sup> Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer," <u>Journal of Clinical Oncology</u> , Vol. 14, No. 3, pp. 737-744 (1996).	
	10	Borer, J. G. et al., "Heparin-Binding EGF-Like Growth Factor Expression Increases Selectively in Bladder Smooth Muscle in Response to Lower Urinary Tract Obstruction," <u>Laboratory Investigation</u> , Vol. 79, No. 11, pp. 1335-1345 (1999).	
	11	Carraway, K. L., III et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling," <u>Cell</u> , Vol. 78, pp. 5-8 (1994).	
	12	Carraway, K. L., III et al., "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases," <u>Nature</u> , Vol. 387, pp. 512-516 (1997).	
	13	Casterella, P. J., M.D. et al., "Prevention of Coronary Restenosis," <u>Cardiology In Review</u> , Vol. 7, No. 4, pp. 219-231 (1999).	
	14	Cerutis, D. R. et al., "Lysophosphatidic acid and EGF stimulate mitogenesis in human airway smooth muscle cells," <u>Am. J. Physiol.</u> , Vol. 273, pp. L10-L15 (1997).	
	15	Chang, H. et al., "Ligands for ErbB-family receptors encoded by a neuregulin-like gene," <u>Nature</u> , Vol. 387, pp. 509-511 (1997).	
	16	Cohen, M. D. et al., "TGF-β1 Modulates Human Airway Smooth-Muscle Cell Proliferation Induced by Mitogens," <u>Am. J. Respir. Cell Mol. Biol.</u> , Vol. 16, pp. 85-90 (1997).	
	17	Earp, H. S. et al., "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research," <u>Breast Cancer Research and Treatment</u> , Vol. 35, pp. 115-132 (1995).	
	18	Elenius, K. et al., "A Novel Juxtamembrane Domain Isoform of HER4/ErbB4," <u>The Journal of Biological Chemistry</u> , Vol. 272, No. 42, pp. 26761-26766 (1997).	
	19	Elenius, K. et al., "Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidylinositol 3-kinase," <u>Oncogene</u> Vol. 18, pp. 2607-2615 (1999).	
MB	20	Freeman, M. R. et al., "Heparin-binding EGF-like Growth Factor Is an Autocrine Growth Factor for Human Urothelial Cells and Is Synthesized by Epithelial and Smooth Muscle Cells in the Human Bladder," <u>J. Clin. Invest.</u> , Vol. 99, No. 5, pp. 1028-1036 (1997).	

EXAMINER		DATE CONSIDERED	2/12/03
----------	--	-----------------	---------

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.072A2	APPLICATION NO. 09/940,101
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT GERRITSEN et al.	GROUP 1641
		FILING DATE August 27, 2001	




RECEIVED  
JAN 07 2002  
TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
MB	21 Friess, H. et al., "Enhanced erbB-3 Expression in Human Pancreatic Cancer Correlates with Tumor Progression," <u>Clinical Cancer Research</u> , Vol. 1, pp. 1413-1420 (1995).
	22 Gorman, C. M. et al., "Transient Production of Proteins Using an Adenovirus Transformed Cell Line," <u>DNA and Protein Engineering Techniques</u> , Vol. 2, No. 1, pp. 3-10 (1990).
	23 Groenen, L. C. et al., "Structure-Function Relationships for the EGF/TGF- $\alpha$ Family of Mitogens," <u>Growth Factors</u> , Vol. 11, pp. 235-257 (1994).
	24 Guy, P. M. et al., "Insect cell-expressed p180 <sup>erbB3</sup> possesses an impaired tyrosine kinase activity," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91, pp. 8132-8136 (1994).
	25 Harari, D. et al., "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase," <u>Oncogene</u> , Vol. 18, pp. 2681-2689 (1999).
	26 Holmes, W. E. et al., "Identification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup> ," <u>Science</u> , Vol. 256, pp. 1205-1210 (1992).
	27 Huang, M. T. F. et al., "Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA," <u>Nucleic Acids Research</u> , Vol. 18, No. 4, pp. 937-947 (1990).
	28 Hudziak, R. M. et al., "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor cells to Tumor Necrosis Factor," <u>Molecular and Cellular Biology</u> , Vol. 9, No. 3, pp. 1165-1172 (1989).
	29 Kaefer, M. et al., "A Nontoxic Diphtheria Toxin Analogue Inhibits Neonatal Bladder Smooth Muscle Cell Proliferation," <u>The Journal of Urology</u> , Vol. 163, pp. 580-584 (2000).
	30 Kalmes, A. et al., "Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor," <u>Circ. Res.</u> , Vol. 87, No. 2, pp. 92-98 (2000).
	31 Kim, Hong-Hee et al., "Epidermal Growth Factor-dependent Association of Phosphatidylinositol 3-Kinase with the erbB3 Gene Product," <u>The Journal of Biological Chemistry</u> , Vol. 269, No. 40, pp. 24747-24755 (1994).
	32 Kraus, M. H. et al., "Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 90, pp. 2900-2904 (1993).
	33 Kraus, M. H. et al., "Isolation and characterization of ERBB3, a third member of the ERBB / epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 86, pp. 9193-9197 (1989).
	34 Kunkel, T. A., "Rapid and efficient site-specific mutagenesis without phenotypic selection," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 82, pp. 488-492 (1985).
	35 Lee, D. C. et al., "Transforming Growth Factor $\alpha$ : Expression, Regulation, and Biological Activities," <u>Pharmacological Reviews</u> , Vol. 47, No. 1, pp. 51-85 (1995).
	36 Lemke, G., "Neuregulins in Development," <u>Molecular and Cellular Neuroscience</u> , Vol. 7, pp. 247-262 (1996).
	37 Lemoine, N. R. et al., "Expression of the ERBB3 gene product in breast cancer," <u>Br. J. Cancer</u> , Vol. 66, pp. 1116-1121 (1992).
	38 Lemoine, N. R. et al., "The erbB-3 Gene in Human Pancreatic Cancer," <u>Journal of Pathology</u> , Vol. 168, pp. 269-273 (1992).
	39 Lewis, G. D. et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness," <u>Cancer Research</u> , Vol. 56, pp. 1457-1465 (1996).
	40 Morrissey, T. K. et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185 <sup>erbB2</sup> ," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 92, pp. 1431-1435 (1995).
	41 Oue, T. et al., "Smooth Muscle Cell Hypertrophy versus Hyperplasia in Infantile Hypertrophic Pyloric Stenosis," <u>Pediatric Research</u> , Vol. 45, No. 6, pp. 853-857 (1999).
	42 Plowman, G. D. et al., "Heregulin induces tyrosine phosphorylation of HER4/p180 <sup>erbB4</sup> ," <u>Nature</u> , Vol. 366, pp. 473-475 (1993).
	43 Plowman, G. D. et al., "Ligand-specific activation of HER4/P180 <sup>erbB4</sup> , a fourth member of the epidermal growth factor receptor family," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 90, pp. 1746-1750 (1993).
	44 Poller, D. N. et al., "Production and Characterization of a Polyclonal Antibody to the c-erbB-3 Protein: Examination of c-erbB-3 Protein Expression in Adenocarcinomas," <u>Journal of Pathology</u> , Vol. 168, pp. 275-280 (1992).
	45 Rajkumar, T. et al., "Expression of the C-erbB-3 Protein in gastrointestinal Tract Tumours Determined by Monoclonal Antibody," <u>Journal of Pathology</u> , Vol. 170, pp. 271-278 (1993).
	46 Rosanio, S. et al., "Prevention of restenosis after Percutaneous Coronary Interventions: The Medical Approach," <u>Thromb Haemost</u> , Vol. 82, pp. 164-170 (1999).
MB	47 Ross, R. et al., "Platelet-derived growth factor and its role in health and disease," <u>Phil. Trans. R. Soc. Lond.</u> , Vol. B 327, pp. 155-169 (1990).

EXAMINER	DATE CONSIDERED
	2/12/03

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


SHEET 3 OF 3  
RECEIVED  
JAN 07 2002  
TECH CENTER 1600/2900



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. GENENT.072A2	APPLICATION NO. 09/940,101
	APPLICANT GERRITSEN et al.	
	FILING DATE August 27, 2001	GROUP 1641

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
MB	48	Sanidas, E. E. et al., "Expression of the c-erbB-3 Gene Product in Gastric Cancer," <u>Int. J. Cancer</u> , Vol. 54, pp. 935-940 (1993).
	49	Sartor, C. I. et al., "HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells," <u>Molecular and Cellular Biology</u> , Vol. 21, No. 13, pp. 4265-4275 (2001).
	50	Schaefer, G. et al., "γ-Herregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175," <u>Oncogene</u> , Vol. 15, pp. 1385-1394 (1997).
	51	Shima H. et al., "Increased Local Synthesis of Epidermal Growth Factors in Infantile Hypertrophic Pyloric Stenosis," <u>Pediatric Research</u> , Vol. 47, No. 2, pp. 201-207 (2000).
	52	Slamon, D. J. et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene," <u>Science</u> , Vol. 235, pp. 177-182 (1987).
	53	Slamon, D. J., "Studies of the HER-2/ <i>neu</i> Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> , Vol. 244, pp. 707-712 (1989).
	54	Sliwkowski, M. X. et al., "Coexpression of <i>erbB2</i> and <i>erbB3</i> Proteins Reconstitutes a High Affinity Receptor for Heregulin," <u>The Journal of Biological Chemistry</u> , Vol. 269, No. 20, pp. 14661-14665 (1994).
MB	55	Zhang, D. et al., "Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 94, pp. 9562-9567 (1997).

W:\DOCS\GRD\GRD-6740.DOC  
102901

EXAMINER 	DATE CONSIDERED 2/12/03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	